Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Total Non-Current Liabilities for the year ending March 31, 2024: USD 4.06 M

Mangalam Drugs & Organics Limited Total Non-Current Liabilities is USD 4.06 M for the year ending March 31, 2024, a -21.18% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Mangalam Drugs & Organics Limited Total Non-Current Liabilities for the year ending March 31, 2023 was USD 5.15 M, a -18.13% change year over year.
Mangalam Drugs & Organics Limited Total Non-Current Liabilities for the year ending March 31, 2022 was USD 6.29 M, a 89.93% change year over year.
Mangalam Drugs & Organics Limited Total Non-Current Liabilities for the year ending March 31, 2021 was USD 3.31 M, a 44.55% change year over year.
Mangalam Drugs & Organics Limited Total Non-Current Liabilities for the year ending March 31, 2020 was USD 2.29 M, a -30.57% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Petrochemicals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years